Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco- and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a variety of in vitro tests under various conditions, which makes a quantitative comparison questionable. METHOD: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRalpha expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). RESULTS AND CONCLUSIONS: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the Delta1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16alpha-methyl or 16beta-methyl group). Almost ideal GCs in terms of missing MC effects, as defined by our in vitro assay, are therefore prednylidene, budesonide, beclomethasone and betamethasone.The MC potency of a steroid is increased by a 9alpha- or a 6alpha-fluoro substituent. A hydrophilic substituent in position 16 (like 16-hydroxylation in triamcinolone) decreases both MC and GC properties. As no substituent that leads to an isolated reduction of GC activity could be characterized in our experiments, 9alpha-fluorocortisol, the most frequently used steroid for MC substitution, seems to be the best choice of available steroids for this purpose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“For example, regarding triamcinolone, its relatively low receptor affinity, both for MRs and GRs, contrasts with its high in vivo potency [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Furthermore, the presence of the 6α-methyl group diminishes the MC activity in vivo, as shown for 6α-methylprednisolone, which presents lower MC activity, but higher GC activity compared with prednisolone [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Functional domains of the human glucocorticoid receptor
Giguère, V., Hollenberg, S. M., Rosenfeld, M. G., & Evans, R. M. (1986) · Cell · doi:10.1016/0092-8674(86)90339-9 · Cited by 918
Differential Recognition of Target Genes by Nuclear Receptor Monomers, Dimers, and Heterodimers*
GLASS, C. K. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-391 · Cited by 829
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Chandler, V. L., Maler, B. A., & Yamamoto, K. R. (1983) · Cell · doi:10.1016/0092-8674(83)90430-0 · Cited by 667
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110033251406 · Cited by 541
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor
Reichardt, H. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7168 · Cited by 429
Transcriptional cross-talk, the second mode of steroid hormone receptor action
Göttlicher, M., Heck, S., & Herrlich, P. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050242 · Cited by 388
Cited by
Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.120 · Cited by 922
“Furthermore, PMD patients demonstrate a blunted response to fludrocortisone, a mixed mineralocorticoid/ glucocorticoid agonist (12, 14), high rates of non-suppression on challenge with dexamethasone, with particularly high post-dexamethasone cortisol levels (13).”
BackgroundSchiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
“active glucocorticoid [74,75], while the 11-keto androgens are more potent than their 11β-hydroxy counterparts [76].”
A users guide to HPA axis research
Spencer, R. L., & Deak, T. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.014 · Cited by 405
“1 nM), cortisol and corticosterone with a lower affinity (Kd ~3-5 nM), and aldosterone with a much lower affinity (151,152).”
Early-life stress and HPA axis trigger recurrent adulthood depression
Juruena, M. F. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.10.020 · Cited by 253
“[87] contrasted the MR and GR properties of different steroids that are regularly used in clinical practice in the equal in vitro test system complemented by a system to test the steroid binding affinities (see Fig.”
BackgroundMethodInfluentialTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“In contrast, a hydrophilic substituent at position 16 decreases both MC and GC properties (20).”
Background
Metadata
- Authors
- Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Institute of Human Nutrition (DE)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 151
- Issue
- 3
- Pages
- 397-406
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2102136926
- Cited by
- 212
- References
- 51
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 15 · 2022: 12 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 10 · 2016: 13 · 2015: 10 · 2014: 18 · 2013: 5 · 2012: 11
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- glucocorticoid receptor, mineralocorticoid receptor, synthetic glucocorticoids, mineralocorticoid activity, structure-activity relationship, prednisolone, budesonide, beclomethasone, betamethasone, triamcinolone, steroid binding affinity
- MeSH terms
- Animals, Anti-Inflammatory Agents, Cells, Cultured, Chlorocebus aethiops, Dexamethasone, Glucocorticoids, Humans, Hydrocortisone, Kidney, Prednisolone, Pregnadienes, Receptors, Glucocorticoid, Transfection, Receptors, Mineralocorticoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. https://app.cochat.ai/papers/10.1530/eje.0.1510397
- The paper
- Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V. (2004). Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1510397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.